LianBio Sponsored ADR (LIANY)
OTHER OTC:LIANY
Top Page
No summary available
Positive Factors
Strong Cash Reserves
Strong cash reserves provide financial resilience, allowing LianBio to invest in strategic initiatives and weather operational challenges.
Negative Factors
Lack of Revenue Generation
Persistent lack of revenue generation raises concerns about LianBio's ability to sustain operations without strategic changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Cash Reserves
Strong cash reserves provide financial resilience, allowing LianBio to invest in strategic initiatives and weather operational challenges.
Read all positive factors
LianBio Sponsored ADR (LIANY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.64M
Dividend YieldN/A
Average Volume (3M)120.02K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,062,640
10 Day Avg. Volume90,792
30 Day Avg. Volume120,018
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio7.66
Enterprise Value/Market Cap-2.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit30.36
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LianBio Sponsored ADR Business Overview & Revenue Model
Company Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment o...
How the Company Makes Money
LianBio generates revenue primarily through strategic partnerships and collaboration agreements with global pharmaceutical and biotechnology companies. The company acquires the rights to develop and commercialize promising drug candidates in speci...
LianBio Sponsored ADR Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.27M | -801.40K | -1.33M | -1.00M | -526.00K | -76.13K |
| EBITDA | 312.20M | 3.26M | 312.91M | -109.49M | -195.52M | -134.90M |
| Net Income | 314.03M | 2.48M | 311.14M | -110.16M | -196.56M | -139.84M |
Balance Sheet | ||||||
| Total Assets | 617.96M | 63.72M | 617.96M | 319.96M | 426.33M | 279.29M |
| Cash, Cash Equivalents and Short-Term Investments | 567.37M | 51.70M | 567.37M | 302.36M | 383.24M | 254.35M |
| Total Debt | 2.46M | 0.00 | 2.46M | 4.34M | 4.83M | 1.88M |
| Total Liabilities | 36.77M | 859.00K | 36.77M | 26.31M | 39.01M | 27.57M |
| Stockholders Equity | 581.20M | 62.87M | 581.20M | 259.87M | 353.55M | 216.95M |
Cash Flow | ||||||
| Free Cash Flow | 258.56M | 3.75M | 258.56M | -100.91M | -165.12M | -99.20M |
| Operating Cash Flow | 258.94M | 3.75M | 258.94M | -99.07M | -164.17M | -98.31M |
| Investing Cash Flow | 99.31M | 128.85M | 99.31M | -69.12M | -156.14M | -887.52K |
| Financing Cash Flow | 1.78M | -550.70M | 1.78M | 1.71M | 313.69M | 310.29M |
LianBio Sponsored ADR Technical Analysis
Neutral
0.12
Price Trends
0.12
Positive
0.10
Positive
0.08
Positive
Market Momentum
<0.01
Positive
44.47
Neutral
16.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIANY, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.12, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 16.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LIANY.
LianBio Sponsored ADR Risk Analysis
LianBio Sponsored ADR disclosed 114 risk factors in its most recent earnings report. LianBio Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LianBio Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
LIANY
LianBio Sponsored ADR
0.13
0.11
525.00%
VIVS
VivoSim Labs
1.71
-0.25
-12.76%
PMCB
PharmaCyte Biotech
0.71
-0.49
-41.08%
SPRC
SciSparc Ltd.
3.59
-49.70
-93.26%
PLRZ
Polyrizon Ltd.
12.30
-525.45
-97.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―